USD10
EXEL Ações
Sobre ExelixisExelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
USD10
EXEL Ações
Sobre ExelixisExelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Estatísticas
JANELA DE NEGOCIAÇÃO
Fechado
ABRE ÀS
Sem dados suficientes
CAPITALIZAÇÃO DE MERCADO
US$ 11,13 bi
PREÇO ABERTO
US$ 42,36
BAIXO (1 A)
US$ 32,38
ALTO (1 A)
US$ 49,62
BAIXO (24H)
US$ 41,49
ALTO (24H)
US$ 42,70
VOLUME (24H)
US$ 1,76 mi
3,48%
Histórico de preços
Time | Price | Change |
|---|---|---|
Hoje | US$ 42,36 | |
1 dia | US$ 41,53 | 0,00% |
1 semana | US$ 41,27 | |
1 mês | US$ 42,66 | |
1 ano | US$ 36,92 |
